Cytosorbents Corporation (FRA:HQE1)

Market Cap	40.52M
Revenue (ttm)	31.52M
Net Income (ttm)	-8.75M
Shares Out	n/a
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.6530
Previous Close	0.6520
Day's Range	0.6530 - 0.6530
52-Week Range	0.5060 - 1.2240
Beta	n/a
RSI	53.86
Earnings Date	Mar 12, 2026

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, su...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 1997
• Employees: 149
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HQE1

Financial Performance

In 2024, Cytosorbents's revenue was $35.59 million, an increase of 14.51% compared to the previous year's $31.08 million. Losses were -$20.72 million, -29.16% less than in 2023.

Financial numbers in USD